StockData
Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock

RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$0.45−0.02 (-4.36%)

Close on Oct 19, 2026Market cap $5.94MP/E –Yield –

Reviva Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Reviva Pharmaceuticals's total debt was $44.39K at Sep 30, 2026. For fiscal 2025 it was $406.88K, down 11.2% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$406.88K-11.2%
FY2024Dec 31, 2024$458.15K–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$44.39K–
Q2 FY2026Jun 30, 2026$144.09K+27.2%
Q1 FY2026Mar 31, 2026$231.27K+3.1%
Q4 FY2025Dec 31, 2025$406.88K-11.2%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$113.25K-45.4%
Q1 FY2025Mar 31, 2025$224.30K-32.4%
Q4 FY2024Dec 31, 2024$458.15K–
Q3 FY2024Sep 30, 2024$83.00K-62.7%
Q2 FY2024Jun 30, 2024$207.50K-6.7%
Q1 FY2024Mar 31, 2024$332.00K-50.3%
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$222.50K–
Q2 FY2023Jun 30, 2023$222.50K–
Q1 FY2023Mar 31, 2023$667.50K–
Q4 FY2022Dec 31, 2022$0–

More Reviva Pharmaceuticals figures

See a number that looks wrong?